At the time of writing, Dyne Therapeutics Inc [DYN] stock is trading at $14.70, up 5.08%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DYN shares have gain 22.91% over the last week, with a monthly amount glided 56.38%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Evercore ISI started tracking the stock with Outperform rating on May 29, 2025, and set its price target to $46. On March 12, 2025, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $50 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $50 on March 07, 2025. Robert W. Baird initiated its recommendation with a Outperform and recommended $46 as its price target on December 13, 2024. RBC Capital Mkts started tracking with a Outperform rating for this stock on November 26, 2024, and assigned it a price target of $45. In a note dated October 24, 2024, JP Morgan downgraded an Neutral rating on this stock and revised its target price from $43 to $35.
For the past year, the stock price of Dyne Therapeutics Inc fluctuated between $6.36 and $47.45. Currently, Wall Street analysts expect the stock to reach $42.67 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $14.70 at the most recent close of the market. An investor can expect a potential return of 190.27% based on the average DYN price forecast.
Analyzing the DYN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.53 and Total Capital is -0.58. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.15 points at the first support level, and at 13.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.13, and for the 2nd resistance point, it is at 15.56.
Ratios To Look Out For
It is important to note that Dyne Therapeutics Inc [NASDAQ:DYN] has a current ratio of 20.35. Also, the Quick Ratio is 20.35, while the Cash Ratio stands at 13.94.
Transactions by insiders
Recent insider trading involved Cox John, CEO & President, that happened on Jun 05 ’25 when 4060.0 shares were sold. Chief Medical Officer, Kerr Douglas completed a deal on Jun 05 ’25 to sell 1342.0 shares. Meanwhile, Chief Commercial Officer Friedl-Naderer Johanna sold 146.0 shares on Jun 05 ’25.
